Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

BACKGROUND: MAPK inhibitors (MAPKi) are active in BRAF-mutant metastatic melanoma patients, but the extent of response and progression-free survival (PFS) is variable, and complete responses are rare. We sought to examine the patterns of response and progression in patients treated with targeted the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Menzies, Alexander M., Haydu, Lauren E., Carlino, Matteo S., Azer, Mary W. F., Carr, Peter J. A., Kefford, Richard F., Long, Georgina V.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2014
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882277/
https://ncbi.nlm.nih.gov/pubmed/24400126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0085004
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki